Price Alert

Replimune Group Inc. (REPL)

NASDAQ: REPL · Real-Time Price · USD

5.67

0.08 (1.34%)

At close: Aug 22, 2025, 3:59 PM

5.70

0.53%

After-hours: Aug 22, 2025, 07:43 PM EDT

1.34% (1D)

Bid	4.12
Market Cap	442.58M
Revenue (ttm)	1.47M
Net Income (ttm)	-280.22M
EPS (ttm)	-3.24
PE Ratio (ttm)	-1.75
Forward PE	-1.76
Analyst	Hold

Ask	7.16
Volume	2,214,242
Avg. Volume (20D)	9,040,274
Open	5.62
Previous Close	5.59
Day's Range	5.55 - 5.82
52-Week Range	2.68 - 17.00
Beta	0.67

About REPL

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol REPL

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for REPL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Replimune Group Inc. is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+10.68%

Replimune shares are trading higher, reversing aft... Unlock content with Pro Subscription

3 weeks ago

+101.33%

Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.

News

1 week ago · businesswire.com

NASDAQ: REPL: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Replimune Group, Inc.

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Replimune...

2 weeks ago · fool.com

Replimune (REPL) Q1 Loss Widens 61%

2 weeks ago · seekingalpha.com

Replimune Group: The Prospects For FDA Approval After Rejection

Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in refractory melanoma. The company's pipeline is centered on RP1, making the rece...

2 weeks ago · benzinga.com

Why Is Replimune Stock Trading Lower On Monday?

On Monday, Replimune Group Inc. REPL is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage.

4 weeks ago · businesswire.com

REPL LEGAL UPDATE: Replimune Group, Inc. Sued after FDA Response Letter -- Investors with Losses are Notified to Contact BFA Law before September 22 Class Action Deadline

NEW YORK--(BUSINESS WIRE)---- $REPL #Attorney--Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain o...